



US005889056A

United States Patent [19][11] **Patent Number:** **5,889,056****Hodson et al.**[45] **Date of Patent:** **Mar. 30, 1999**[54] **ENZYME INHIBITORS**

[75] Inventors: **Harold Francis Hodson; Richard Michael John Palmer; David Alan Sawyer**, all of Kent; **Richard Graham Knowles**, Hertfordshire; **Karl Witold Franzmann**, London; **Martin James Drysdale**, Hertfordshire; **Patricia Ifeyinwa Davies**, London; **Helen Alice Rebecca Clark**, Surrey, all of United Kingdom; **Barry George Shearer**, Cary, N.C.; **Steven Smith**, Hertfordshire, United Kingdom

[73] Assignee: **Glaxo Wellcome Inc.**, Research Triangle Park, N.C.

[21] Appl. No.: **750,679**

[22] PCT Filed: **Jun. 14, 1995**

[86] PCT No.: **PCT/GB95/01378**

§ 371 Date: **Dec. 27, 1996**

§ 102(e) Date: **Dec. 27, 1996**

[87] PCT Pub. No.: **WO95/34534**

PCT Pub. Date: **Dec. 21, 1995**

[30] **Foreign Application Priority Data**

Jun. 15, 1994 [EP] European Pat. Off. 94304314
May 15, 1995 [GB] United Kingdom 9509774

[51] **Int. Cl.**⁶ **A61K 31/195**

[52] **U.S. Cl.** **514/562; 514/550; 560/150; 562/556**

[58] **Field of Search** **560/150; 562/556; 514/550, 562**


[56] **References Cited****FOREIGN PATENT DOCUMENTS**

2 727 111 5/1996 France .

Primary Examiner—Samuel Barts
Attorney, Agent, or Firm—Nixon & Vanderhye

[57] **ABSTRACT**

A compound of formula (I)



wherein

R¹ is a C₁₋₆ straight or branched chain alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl group, a C₃₋₆ cycloalkyl group or a C₃₋₆ cycloalkylC₁₋₆ alkyl group, each optionally substituted by one to three groups independently selected from: —CN; —NO₂; a group —COR² wherein R² is hydrogen, C₁₋₆ alkyl, —OR³ wherein R³ is hydrogen or C₁₋₆ alkyl or NR⁴R⁵ wherein R⁴ and R⁵ are independently selected from hydrogen or C₁₋₆ alkyl; a group —S(O)_mR⁶ wherein m is 0, 1 or 2, R⁶ is hydrogen, C₁₋₆ alkyl, hydroxy or NR⁷R⁸ wherein R⁷ and R⁸ are independently hydrogen or C₁₋₆ alkyl; a group PO(OR⁹)₂ wherein R⁹ is hydrogen or C₁₋₆ alkyl; a group NR¹⁰R¹¹ wherein R¹⁰ and R¹¹ are independently selected from hydrogen, C₁₋₆ alkyl, —COR¹² wherein R¹² is hydrogen or C₁₋₆ alkyl, or —S(O)_mR¹³ wherein m' is 0, 1 or 2 and R¹³ is hydrogen or C₁₋₆ alkyl; halo; or a group —OR¹⁴ wherein R¹⁴ is hydrogen, C₁₋₆ alkyl optionally substituted by one to three halo atoms, C₆₋₁₀ aryl or —COR¹⁵ wherein R¹⁵ is hydrogen or C₁₋₆ alkyl; p is 2 or 3, q is 1 or 2 and n is 0 or 1 and all salts, esters, amides and physiologically acceptable prodrugs thereof; pharmaceutical uses and formulations therefor; and processes for their preparation are disclosed.

9 Claims, No Drawings